Oral GLP-1 Candidate Safiglipron Meets Phase 3 Glucose-Control Endpoint Against Dapagliflozin

An October 5 Nature Medicine report details OUTSTAND2, an 810participant comparison of a nonpeptide oral GLP1 agonist with dapagliflozin, with important distinctions between noninferiority and superiority.

For research use only. Not for human consumption.